Phathom Pharmaceuticals Reports Strong Revenue Growth in Q1 2026

Phathom Pharmaceuticals (PHAT) reported more than double year-over-year revenue growth for Q1 2026, driven by a strategic shift to engage gastroenterologists. The company reiterated its full-year net revenue guidance of $320 million to $345 million and expects non-GAAP operating profitability in the second half of 2026.

By Moby Intelligence Fri, May 1, 2026 at 3:48 AM GMT+3 3 min read · Yahoo Finance · May 1, 2026, 00:48 UTC

Phathom Pharmaceuticals Reports Strong Revenue Growth in Q1 2026

Tickers: $PHAT

Topics: clinical trials earnings growth strategy market share pharmaceuticals sales force

Read the full article at Yahoo Finance

More World news

Jensen Huang Resigns as Nvidia CEO Amid Allegations of Chinese Espionage The Verge · November 12, 2026, 16:30 UTC
Rising New Vehicle Monthly Payments Pose Affordability Risks for Ford and General Motors Motley Fool · November 12, 2026, 16:33 UTC
SpaceX Shares Rise Following Nvidia CEO Jensen Huang Resignation Motley Fool · November 12, 2026, 16:34 UTC
tZERO Receives CFTC Approval for Derivatives Exchange and Clearing Operations PR Newswire · November 12, 2026, 16:36 UTC
enGene Therapeutics Shares Surge Following Positive Mid-Stage Trial Data and Piper Sandler Upgrade Seeking Alpha · November 12, 2026, 16:33 UTC
Former Nvidia CEO Jensen Huang to Testify Before Congress Regarding Export Controls and Security Concerns TechCrunch · November 12, 2026, 16:36 UTC
Nobu Hospitality and Infracorp Partner to Develop Luxury Destination in Bahrain PR Newswire · November 12, 2026, 16:34 UTC
Serco Group Announces $292 Million Acquisition of QinetiQ's U.S. Business Seeking Alpha · November 12, 2026, 16:30 UTC
Ag Growth International Targets $30M in Cost Savings Amid Divergent Business Performance Seeking Alpha · November 12, 2026, 16:30 UTC
Qualstar Reports Q3 Non-GAAP EPS of $0.09 and Revenue of $2.04 Million Seeking Alpha · November 12, 2026, 16:31 UTC